Literature DB >> 22926540

[Mycophenolate mofetil seems to be superior to azothioprine in maintenance therapy of lupus nephritis].

M Schmalzing1, I Kötter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22926540     DOI： 10.1007/s00393-012-1022-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  4 in total

1.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Authors:  Ellen M Ginzler; Mary Anne Dooley; Cynthia Aranow; Mimi Y Kim; Jill Buyon; Joan T Merrill; Michelle Petri; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; Gerald B Appel
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

2.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

3.  Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis.

Authors:  Kai Chung Tse; Colin S O Tang; Man Fai Lam; Desmond Y H Yap; Tak Mao Chan
Journal:  J Rheumatol       Date:  2009-01       Impact factor: 4.666

4.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.